Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betaprodine is a synthetic opioid analgesic chemically related to meperidine, notable for its rapid onset and short duration of action. It acts primarily as an agonist at mu-opioid receptors in the central nervous system, leading to inhibition of neurotransmitter release involved in pain transmission and resulting in analgesia. Betaprodine has been used experimentally for pain management in settings such as obstetrics, pre-operative medication, minor surgical procedures, and dental procedures. It is significantly more potent than morphine (up to 50 times stronger) but produces more euphoria and side effects compared to its stereoisomer alphaprodine. Betaprodine is classified as a Schedule I controlled substance under the DEA due to its high potential for abuse and lack of accepted medical use in the United States[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betaprodine.